DGAP-News: Neovacs S.A. / Key word(s): Financing NEOVACS SECURES A NEW EQUITY LINE FINANCING WITH KEPLER CHEUVREUX 21.11.2014 / 08:00 --------------------------------------------------------------------- PRESS RELEASE NEOVACS SECURES A NEW EQUITY LINE FINANCING WITH KEPLER CHEUVREUX Paris, November 21, 2014 - NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the arrangement of a multiyear equity financing with Kepler Cheuvreux, as authorized by the shareholder's Annual General Meeting of May 19, 2014, following the agreement announced in a recent press release. Proceeds of the financing will be used to fund the clinical development of Neovacs' therapeutic vaccines portfolio, primarily a phase IIb clinical trial of IFNα-Kinoid in Lupus and preclinical projects. The funds from Kepler Cheuvreux could be supplemented by additional proceeds from licensing agreements on therapeutic candidates in the Company's portfolio. "With this new agreement with Kepler Cheuvreux, we are securing Neovacs' long term financing in a flexible arrangement and through a tool tailored to our needs. Our financial position will evolve based on the licensing deals that we plan to create for TNF-Kinoid and IFNα-Kinoid - hence the advantage of having access to a flexible equity facility, which we will only use if needed" commented Miguel Sieler, Neovacs Chief Executive Officer. Over the next 12 months, Kepler Cheuvreux will subscribe such number of shares as will allow Neovacs to receive EUR7 million in equity, i.e. approximately 2.15 million new shares or 9.9% of the current share capital*, subject to exercise conditions agreed between the parties. These provisions will allow Neovacs to retain control over the timing of this facility granted by Kepler Cheuvreux. The issuance price of the new Neovacs shares will reflect the share market price at the time of issuance, minus a maximum 7% discount. This discount will enable Kepler Cheuvreux to instantly underwrite the shares despite possible market volatility. Acting as financial intermediary, Kepler Cheuvreux does not aim to remain a shareholder of the Company. For reference, should the proceeds of this facility actually amount to EUR7 million, based on a share price of EUR3.50**, a shareholder currently holding 1.0% of the Company's share capital would see his/her ownership reduced to 0.91%***. Under the agreement with Kepler Cheuvreux, Neovacs could utilize two additional tranches of equity financing, totaling EUR6.5 million each, as from November 20, 2015 and over a fixed period of 18 months, based on the same terms as the equity line announced today. Neovacs intends to draw down on these equity lines only if needed, in the best interest of the Company and its shareholders. It should be noted that as of November 20, 2013, the equity line arranged with Kepler Cheuvreux in December 2013 has been fully drawn down. * Based on an indicative share price of EUR3.50 ** Triggering the issuance of 2,150,538 new shares *** Based on the number of Neovacs shares as of November 20, 2014 which is 21,819,310 About Neovacs Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that run until at least 2026) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn's disease, whereas IFNα-Kinoid is being developed for the indication of lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, visit www.neovacs.fr Contacts NEOVACS Nathalie Trépo +33 (0)1 53 10 93 00 ntrepo@neovacs.com Press - Financial Communications- Publicis Stéphanie Tabouis +33 (0) 1 44 82 46 35 stéphanie.tabouis@consultants.publicis.fr Kepler Cheuvreux Thierry du Boislouveau +41 22 994 1557 +33 (0)1 53 65 36 85 thierry.du-boislouveau@keplercf.com --------------------------------------------------------------------- 21.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Freiverkehr in Stuttgart; Frankfurt in Open Market End of News DGAP News-Service --------------------------------------------------------------------- 298433 21.11.2014
DGAP-News: NEOVACS SECURES A NEW EQUITY LINE FINANCING WITH
Top 10 Most Recent News Articles
Berlin Heals Puts Microcurrent Therapy to a Real Test
A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....
Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage
Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...
Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play
Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...
Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care
A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...
Continue Reading
Teachers in Space Takes Its Classroom Model Orbital
Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....
Continue Reading
Physiatry or Orthopedics: Sorting Out Pain Care Choices
Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...
Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push
A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...
Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger
A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...
Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes
A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...
Continue Reading
Vertex Extends Genomics Pact With $220M in Potential
Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...
Continue ReadingTop 5 Most Recently Viewed Articles
Impact of Withdrawal on Menthol Cigarette Regulation Efforts
The Trump Administration's Recent Decision Recently, the Trump administration made headlines by withdrawing a previously proposed ban on menthol cigarettes in the United States. This decision marks a significant setback for health regulators and activists who have long been advocating for healthier tobacco policies. Background of the Proposal In April 2022, the Food and...
Continue Reading
Carta Healthcare Secures Gold by Innovating Clinical Data
Tackling a Stubborn Healthcare Pain Point Let's face it: the healthcare industry's data management game has been sweating buckets over a Herculean task for years. A staggering $10-15 billion gets burned annually thanks to inefficient clinical data abstraction. Today's hero of this tale? Carta Healthcare, which just snagged a shining Gold at the 2026 Stevie Awards in...
Continue Reading
SentinelOne Earns Prestigious Recognition from Gartner for 2024
SentinelOne's Recent Achievement in Cloud Security SentinelOne (NYSE: S), a prominent player in the field of AI-driven security solutions, has recently been acknowledged as a Customers' Choice in the 2024 Gartner® Peer Insights™ report specifically for Cloud-Native Application Protection Platforms. This recognition reflects feedback from a broad user base, emphasizing...
Continue Reading
Tingus Goose: A Premium Idle Game Experience on Steam
Exciting Announcement for Gamers The cult phenomenon, Tingus Goose, is making its debut on Steam as a fully enhanced 1.0 edition designed for PC players. Co-published by Playsaurus and Ultraplayers, this adaptation aims to deliver the ultimate idle gaming experience, free from the distractions found in mobile versions. What’s New in Tingus Goose? Unique Gameplay...
Continue ReadingTrackerRMS Launches Innovative Onboarding+ Solution for Staffing
Introducing the New Onboarding+ Solution by TrackerRMS TrackerRMS has taken a significant step in revolutionizing the recruitment landscape with the introduction of its Onboarding+ solution. This innovative tool is designed specifically for recruitment agencies looking to enhance their onboarding process and improve the overall candidate journey. By integrating advanced...
Continue Reading